Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Overall, the response aligns with label content provided for dizziness/somnolence and interaction counseling with CNS depressants (including alcohol/opioids) and for angioedema/hypersensitivity. However, multiple claims about insomnia during therapy, timing relative to dose changes, night-time ambulation/coordination safety, dosing-time modifications, sleep-onset latency, awakenings, and other sleep-pattern effects are unsupported by the provided label sections, reducing overall alignment.
Category Scores
Accurate Statements
Pregabalin can cause sleepiness or sedation in some people.
5.5 Dizziness and Somnolence; 17 Patient Counseling Information ("may cause dizziness and somnolence"; somnolence experienced in trials)
Pregabalin can cause dizziness.
5.5 Dizziness and Somnolence ("may cause dizziness and somnolence"; dizziness frequency provided)
Pregabalin can increase sedation.
5.5 (somnolence); 17 (may cause dizziness, somnolence)
The risk of sedation with pregabalin can rise when it is combined with other sedating drugs/CNS depressants.
5.5 ("Concomitant use... with other central nervous system (CNS) depressants may exacerbate these effects"); 17 CNS Depressants (additive CNS side effects such as somnolence; includes opioid analgesics)
Pregabalin can rarely be associated with angioedema.
5.1 Angioedema (postmarketing reports; includes swelling of face/mouth/neck/throat/larynx; life-threatening reports)
Pregabalin can rarely be associated with serious allergic/hypersensitivity reactions.
5.2 Hypersensitivity Reactions (postmarketing reports; includes serious respiratory symptoms like dyspnea and wheezing; discontinue immediately)
Unsupported Statements
Pregabalin can cause trouble sleeping in some people.
Provided label excerpts do not describe trouble sleeping as an adverse reaction during active therapy; insomnia is mentioned in the context of abrupt/rapid discontinuation (17).
Common sleep- and alertness-related effects include drowsiness/somnolence (sleepiness during the day).
Somnolence is supported, but the provided label excerpt does not explicitly state daytime drowsiness.
Difficulty sleeping or unusual sleep problems are reported in prescribing information for pregabalin products.
Provided label excerpt ties insomnia to abrupt/rapid discontinuation rather than difficulty sleeping during ongoing treatment (17).
Pregabalin can cause sleep disturbances in some people, including insomnia-like symptoms.
No provided label language supports insomnia-like symptoms during ongoing use; insomnia is described with abrupt/rapid discontinuation (17).
If insomnia happens after starting pregabalin or after a dose increase, it is often noticed soon after the medication adjustment.
No provided label language links timing of insomnia to initiation or dose increases.
Pregabalin side effects that commonly interfere with bedtime or nighttime include dizziness.
Provided label excerpt supports dizziness/somnolence generally, but does not state bedtime/nighttime interference or that it is common specifically for bedtime/nighttime.
Pregabalin side effects that commonly interfere with bedtime or nighttime include sleepiness/somnolence.
Provided label excerpt supports somnolence generally, but does not state bedtime/nighttime interference as a labeled concept.
Pregabalin can cause blurred vision and trouble with coordination.
Blurred vision is supported as a counseling point (17), but 'trouble with coordination' is not explicitly supported in the provided label excerpts.
Blurred vision and trouble with coordination from pregabalin can make it feel unsafe or uncomfortable to move around at night.
Provided label excerpts do not mention night-time ambulation safety, coordination-specific effects in that context, or related counseling.
Pregabalin effects can lead to longer time to fall asleep.
No provided label language describing increased time to fall asleep.
Pregabalin effects can lead to more awakenings.
No provided label language describing increased awakenings.
Pregabalin effects can lead to daytime fatigue that makes sleep patterns shift.
No provided label language describing daytime fatigue altering sleep patterns.
Taking pregabalin later in the day can increase next-day grogginess.
No provided label language linking dosing time to next-day grogginess.
Taking pregabalin earlier may reduce nighttime drowsiness.
No provided label language comparing earlier vs later dosing effects on nighttime drowsiness.
Pregabalin is often prescribed multiple times per day.
No dosing frequency information was included in the provided label excerpts.
Changing pregabalin dosing times can sometimes improve sleep quality.
No provided label language supports changing dosing times to improve sleep quality.
Seek urgent medical care if sleepiness becomes extreme, such as being difficult to wake or feeling unusually confused.
Provided label excerpts advise regarding somnolence and driving/operating machinery, and discuss respiratory depression risk; they do not provide the specific extreme-somnolence scenarios or urgent-care instructions phrased this way.
Contradictions
Important Omissions
The evaluation is limited to the provided label excerpts; several high-priority label elements (e.g., contraindications, boxed warnings if any, dosing/administration instructions, and broader warnings/precautions such as respiratory depression details) are not addressed by the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about insomnia during treatment, timing relative to dose changes, and night-time ambulation/coordination could misinform counseling. However, the response includes label-supported information on somnolence/dizziness and the need for caution with CNS depressants, plus label-supported angioedema/hypersensitivity warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple sleep-related claims (insomnia/sleep disturbance during use; timing; dosing-time adjustments; sleep-onset/awakenings; night-time coordination safety) are not supported by the provided label excerpts.
Suggested Improvement
Restrict sleep-related claims to what the provided label excerpts support (dizziness/somnolence; insomnia only in the context of abrupt/rapid discontinuation) and avoid adding dose-timing or night-time coordination/ambulation assertions not present in the labeling excerpts.